...Jingyuan Li; Qian Wang; Chunliu Wu; Xiaoyu Qu; Lei Zhang; Xiaofeng He; Sicong Ma; Miaohan Qiu; Xiaozeng Wang Introduction: The treatment strategy for dual antiplatelet therapy (DAPT) with ticagrelor has been controversial in East Asian patients with acute coronary syndrome (ACS) undergoing...

...Lourdes Vicent; Vanesa Bruña; Carolina Devesa; Iago Sousa-Casasnovas; Miriam Juárez; Luis Alcalá; Patricia Muñoz; Francisco Fernández-Avilés; Manuel Martínez-Sellés Background: Ticagrelor has a bactericidal effect in vitro, and clinical studies suggest a beneficial effect in infections. Our aim...

... intervention treated with prasugrel versus ticagrelor. Methods: Among 7,233 patients enrolled to the Acute Coronary Syndrome Israeli Survey (ACSIS) between 2010 and 2018, we identified 1,126 eligible patients treated with prasugrel and 817 with ticagrelor. Comparison between the groups was performed separately...

...Lucas Chun Wah Fong; Nicholas Ho Cheung Lee; Andrew T. Yan; Ming-Yen Ng Introduction: There have been inconsistent data on the direct comparison of prasugrel and ticagrelor. This meta-analysis was conducted to summarize the current available evidence. Methods: We performed a meta-analysis (PROSPERO...

... professionals and consumers as well as required mandatory reporting by pharmaceutical manufacturers. However, the initial filers and comparative patterns for oral P 2 Y12 platelet inhibitor reporting are unknown. We assessed who generated original FAERS reports for clopidogrel, prasugrel, and ticagrelor in 2015...

...Cai De Jin; Moo Hyun Kim; Junghee Bang; Victor Serebruany Background: The optimal dosing of novel oral P2Y 12 receptor platelet inhibitors such as prasugrel or ticagrelor is unclear and especially challenging in East Asians. We hypothesize that half-dose prasugrel and ticagrelor may be sufficient...

...) patients, receiving clopidogrel, prasugrel, or ticagrelor. Methods: This was a prospective, observational, multicenter, cohort study of ACS patients undergoing percutaneous coronary interventions (PCI) with IRF (creatinine clearance <60 mL/min by Cockroft-Gault equation), who were recruited...

... and myocardial perfusion were almost identical after ticagrelor or clopidogrel, the small (n = 24) single-center PLATO-P suggested that ticagrelor achieved a highly significantly greater antiplatelet effect compared to clopidogrel after loading in patients enrolled in the same trial and at similar time points...

...Victor L. Serebruany; Dirk Sibbing; James J. DiNicolantonio Context: Oral reversible platelet P2Y12 receptor inhibitors (ticagrelor and elinogrel) cause double-digit rates of dyspnea, while irreversible oral antiplatelet drugs (aspirin, ticlopidoine, clopidogrel, and prasugrel) or intravenous...

... such as prasugrel and ticagrelor are even recommended over clopidogrel in certain clinical guidelines. Despite the fact that clopidogrel is fraught with significant variability in on-treatment platelet reactivity, the novel P2Y 12 receptor antagonists come at the price of increased side effects and cost. Therefore...

...Victor L. Serebruany; James J. DiNicolantonio; Mehmet Mustafa Can; Igor V. Pershukov; Wiktor Kuliczkowski Current guidelines offer a choice of P2Y 12 receptor antagonist among clopidogrel, prasugrel or ticagrelor on top of aspirin (ASA) for dual antiplatelet therapy (DAPT) in patients after acute...

...Kristina Torngren; Jenny Öhman; Hanna Salmi; Johan Larsson; David Erlinge Objective: The novel P2Y 12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients...

...James J. DiNicolantonio; Victor L. Serebruany Context: Much emphasis has been placed on a ticagrelor-aspirin (ASA) interaction in the Platelet Inhibition and Patient Outcomes (PLATO) trial, despite this particular interaction being inconclusive. However, a potential ticagrelor-statin interplay...

.... Ticagrelor Mortality rates Acute coronary syndromes Clinical trials Controversy continues regarding the interpretation of the relatively high death rates reported in the PLATO (PLATelet Inhibition and Clinical Outcomes) trial [ 1 ], which might importantly affect the benefit inferred from the use...

...Victor L. Serebruany Context: On July 20, 2011, the Food and Drug Administration (FDA) approved ticagrelor (Brilinta™) for use during acute coronary syndromes. The drug labeling includes a ‘black box’ warning for bleeding risks, conventional for antithrombotics, and a unique warning that higher...

... Response Review for ticagrelor. Results: Excluding adjudicated deaths, the distribution for clopidogrel appears more uniform while that for ticagrelor was skewed to the right, suggesting more events were reported after the sponsor censoring end date. PLATO investigators reported 16 unmatched primary...

...Kenneth P. Morgan; Ranjit S. More; Anoop Chauhan Ticagrelor has been shown to be superior to clopidogrel in patients presenting with acute myocardial infarction who undergo early invasive treatment. We discuss a hitherto unreported use of ticagrelor in the management of a patient resistant...

...Victor L. Serebruany Objectives: To summarize the available evidence regarding whether or not a higher aspirin maintenance dose inversely affects the ticagrelor benefit observed in the US cohort of the PLATO trial. Background: In the recent PLATO trial, the daily aspirin dosages in the USA were...

...Victor L. Serebruany The striking success of ticagrelor in PLATO when compared with recent important but far less impressive antiplatelet trials suggests the fundamental difference of ticagrelor from thienopyridines, such as ticlopidone, clopidogrel, and prasugrel. In fact, being a P2Y12 platelet...